Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.43 AUD | -0.82% | +0.83% | -15.92% |
Mar. 05 | Australia shares inch lower as miners weigh; GDP data in focus | RE |
Feb. 28 | Australian Clinical Labs Falls 11% After Trimming Interim Dividend on Lower H1 FY24 EPS | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company is in a robust financial situation considering its net cash and margin position.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.92% | 322M | C | ||
-14.42% | 85.02B | B- | ||
+14.42% | 82.37B | C+ | ||
+9.37% | 29.29B | C+ | ||
-10.31% | 17.21B | B | ||
-0.36% | 16.7B | A- | ||
+1.01% | 15.5B | A- | ||
+4.32% | 12.15B | A- | ||
-2.34% | 12.13B | A- | ||
+31.81% | 12.12B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACL Stock
- Ratings Australian Clinical Labs Limited